npj Breast Cancer

Papers
(The median citation count of npj Breast Cancer is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers445
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer224
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer186
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?160
International survey on invasive lobular breast cancer identifies priority research questions149
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab111
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer110
Biological correlates associated with high-risk breast cancer patients identified using a computational method109
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab96
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer89
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment82
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women81
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer81
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients73
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells72
Immunotherapy for early triple negative breast cancer: research agenda for the next decade68
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors62
Breastfeeding attributable fraction of triple negative breast cancer in the US58
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events56
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models53
Circulating tumor DNA validity and potential uses in metastatic breast cancer51
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays50
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer49
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer48
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer46
Temporal evolution of breast cancer brain metastases treatments and outcomes45
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases43
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines40
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions40
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)39
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer39
Survival outcomes after omission of surgery for ductal carcinoma in situ39
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial39
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice39
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC38
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis38
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer37
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)37
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer34
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature34
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer34
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors33
Understanding metastasis mixed-treatment responses through genomic analyses32
Kataegis in clinical and molecular subgroups of primary breast cancer32
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling31
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer31
Is conservative management of ductal carcinoma in situ risky?30
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center30
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification30
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment29
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models29
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer29
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment29
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin28
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer28
Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 201628
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program28
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer27
Oncogene-mediated metabolic gene signature predicts breast cancer outcome27
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance26
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer26
Cook and Move for Your Life, an eHealth intervention for women with breast cancer25
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies25
Large language model (ChatGPT) as a support tool for breast tumor board25
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer24
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 23
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study22
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer22
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy22
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial22
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies21
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models21
A systematic review of determinants of breast cancer risk among women with benign breast disease21
Prognostic value of structural variants in early breast cancer patients21
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief21
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers20
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer20
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis20
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis20
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer19
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women19
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer19
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer19
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study18
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor18
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases18
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer18
Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer18
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation18
Subclonal heterogeneity and evolution in breast cancer17
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy17
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women17
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer17
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence17
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape17
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry16
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer16
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study16
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer16
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy16
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence16
Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer16
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response16
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer16
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention16
Post-diagnosis weight trajectories and mortality among women with breast cancer15
Artificial intelligence in breast pathology – dawn of a new era15
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer15
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib15
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts15
Proteogenomic characterization of invasive breast tumors in young women15
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study15
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer15
Racial discrimination among women seeking breast cancer care15
Plasma C-peptide mammographic features and risk of breast cancer15
Advancing equitable access to innovation in breast cancer14
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer14
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials14
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer14
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination14
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression14
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial14
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer14
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer14
Genomic landscape of breast cancer in elderly patients14
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer14
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer14
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics14
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer13
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer13
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers13
Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR13
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials13
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings13
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer13
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study13
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment13
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy13
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management13
MammOnc-DB, an integrative breast cancer data analysis platform for target discovery13
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study13
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer13
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients13
An emerging generation of endocrine therapies in breast cancer: a clinical perspective13
Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer13
Genomic landscapes of breast cancer in African populations: a systematic review13
Computerized cognitive training improves cognitive function in primary breast cancer survivors12
Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation12
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden12
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning12
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ12
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease12
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer12
Bridging the gap: ctDNA, genomics, and equity in breast cancer care12
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer12
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning12
Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer12
De-escalation in breast cancer surgery12
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer12
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study12
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function12
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools11
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients11
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer11
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer11
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade11
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study11
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers11
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial11
Author Correction: Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis11
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer10
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer10
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer10
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial10
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial10
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research10
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study10
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes10
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab10
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes10
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer10
A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death10
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy10
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer10
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis10
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis10
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing9
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer9
Mammographic texture features associated with contralateral breast cancer in the WECARE Study9
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients9
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)9
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment9
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer9
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer9
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling9
Allostatic load as a predictor of postoperative complications in patients with breast cancer9
Iminodibenzyl induced redirected COX-2 activity inhibits breast cancer progression9
Immunotherapy in breast cancer: an overview of current strategies and perspectives8
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib8
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies8
LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer8
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer8
Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer8
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets8
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer8
Breast cancer dormancy is associated with a 4NG1 state and not senescence8
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study8
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study8
CBD-oil as a potential solution in case of severe tamoxifen-related side effects8
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis8
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer8
Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis8
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy8
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer8
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy8
Modeling tumor relapse using proliferation tracing and ablation transgenic mouse8
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy7
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models7
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer7
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets7
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)7
The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue7
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer7
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)7
Altered ribosomal profile in acquired resistance and reversal associates with pathological response to chemotherapy in inflammatory breast cancer7
Predicting pathologic ≥N2 disease in women with breast cancer7
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC7
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors7
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ7
NR4A3 potentials M1-like macrophage polarization to facilitate anti-tumor immune responses in breast cancer7
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer6
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification6
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer6
Triple negative breast cancer: Pitfalls and progress6
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis6
Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer6
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 405026
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer6
HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer6
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing6
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients6
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype6
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness6
Integrative multiomics-histopathology analysis for breast cancer classification6
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis6
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial6
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer6
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer6
Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer6
Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trial6
0.099512100219727